Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Erica L. Mayer, F.-C. Bidard, Y.H. Park, W Janni, X. Cynthia, Massimo Cristofanilli, Hiroji Iwata, G. Bianchini, K. Kalinsky, S. Chia, Adam Brufsky, P.A. Fasching, Zbigniew Nowecki, S.-C. Chen, Javier Pascual, L. Moreau, Manuel Ruíz‐Borrego, A. Shai, Nuri Karadurmuş, Joohyuk Sohn, Yanyan Zhu, Isobel Leddin, M.S. Miralles, Cynthia Huang Bartlett, Nicholas C. Turner